An interferon-gamma, tumor necrosis factor, and interleukin-1-inducible, high-output pathway synthesizing nitric oxide (NO) from L-arginine was recently identified in rodents. High-dose interleukin-2 (IL-2) therapy is known to induce the same cytokines in patients with advanced cancer. Therefore, we examined renal cell carcinoma (RCC; n = 5) and malignant melanoma (MM; n = 7) patients for evidence of cytokine-inducible NO synthesis. Activity of this pathway was evaluated by measuring serum and urine nitrate (the stable degradation product of NO) during IL-2 therapy. IL-2 administration caused a striking increase in NO generation as reflected by serum nitrate levels (10-and 8-fold increase [P less than 0.001, P less than 0.003] for RCC and MM patients, respectively) and 24-h urinary nitrate excretion (6.5-and 9-fold increase [both P less than 0.001] for RCC and MM patients, respectively). IL-2-induced renal dysfunction made only a minor contribution to increased serum nitrate levels. Metabolic tracer studies using L- [guanidino-15N2] 
Introduction
1. Abbreviations used in this paper: BUN, blood urea nitrogen; FE, fractional excretion; GC/MS, gas chromatography-mass spectrometry; LAK, lymphokine-activated killer; MM, malignant melanoma; RCC, renal cell carcinoma; TNF, tumor necrosis factor; TPN, total parenteral nutrition.
feron--y (IFN-y), interleukin 1 (IL-1), and interleukin 6 (2-7). It was observed, in both mice and humans, that normal resting lymphocytes treated with high concentrations of IL-2 developed the ability to kill a wide range of syngeneic and allogeneic tumor cells (8) . IL-2-activated cells were functionally defined as lymphokine-activated killer (LAK) cells and administration of IL-2 plus LAK cells to mice caused regression of established syngeneic tumors (9) . Clinical trials ofIL-2 plus LAK cells or of IL-2 alone demonstrated objective regressions in -25-33% of patients including 5-10% complete remissions in patients with advanced melanoma or renal cell carcinoma (10) . Clinical use of IL-2 therapy, with or without LAK cells, has been limited by the low rate of complete remissions and by severe toxicity that requires intensive care monitoring. Patients receiving IL-2 therapy often develop potentially life-threatening side effects that include fever, chills, hypotension, capillary leak syndrome, as well as evidence of multiple organ system dysfunction, specifically including acute renal insufficiency and cholestatic jaundice (10) .
Studies of rodent cytotoxic activated macrophages as an effector component of cell-mediated immunity resulted in the identification of a cytokine (IFNy and TNF)-inducible pathway that was capable of producing high levels of nitric oxide (NO) and L-citrulline synthesis from L-arginine (11) (12) (13) (14) (15) (16) (17) (18) (for reviews, see references 19 and 20) . NO is a short-lived paramagnetic lipid-soluble gas which, when present in high concentration in the cellular environment, causes widespread ironsulfur nitrosyl complex formation that inhibits certain iron-dependent enzymes (21, 22) (Fig. 1) . NO has been shown to be a biochemical effector of L-arginine-dependent cell-mediated immune responses to neoplastic cells (1 1-13, 16, 17, 19) as well as to certain helminths and intracellular pathogens (20, (23) (24) (25) (26) (27) (28) (29) in rodent cells in vitro.
A constitutive low-output pathway synthesizing small amounts of NO and L-citrulline from L-arginine was also recently identified (30) (31) (32) (33) . NO synthesized from L-arginine by the constitutive NO synthase functions as an intercellular and/ or intracellular signal. For example, NO synthesized by the constitutive isoenzyme of endothelial cells targets a heme moiety associated with soluble guanylate cyclase of vascular smooth muscle cells and mediates functional linkage between these two cell types (34) . Examples ofconstitutive NO synthase activity include modulation of vascular tone (30) and neurotransmission (31) (32) (33) .
NO synthesized by either isoenzyme undergoes oxidative degradation to the stable inorganic nitrogen oxides nitrite [1] [51] 4HbO2 + 4NO-+ 4H+ -~4Hb+ + 4NO3 + 02+ 2H20 from a terminal guanidino nitrogen atom of L-arginine is detected in serum or urine as NO-. The study reported here was undertaken to examine (a) whether IL-2 administration to patients with cancer caused a rise in NO synthesis from L-arginine; (b) whether urine and serum NO-levels could serve as markers of IL-2-stimulated NO generation; and (c) the extent that IL-2-induced renal dysfunction (36, 37) contributed to elevations in serum NO-levels.
Methods
Subjects. The > 75% of predicted), normal bone marrow, and liver and renal func- identified by GC/MS (13) (14) (15) 30) electron paramagnetic resonance spectroscopy (21, 22) except for nitrogen dioxide (NO2), which was detected by another method (13) . The direct synthesis of L-citrulline from L-arginine has been identified with several techniques (12) (13) (14) (15) 58) . The experiments utilizing L-[guanidino-
'4C]arginine (13, 58) are illustrated in the figure. NO formed by reaction [1] can undergo oxidative degradation in aqueous solution (reactions [2] and [3] or react with nonheme iron associated with sulfur atoms to form nitrosyliron-sulfur complexes (reaction [4] ). Although not shown, certain other forms of intracellular iron also complex with NO. (Hibbs et al., unpublished data). NO-entering the vascular system reacts rapidly with oxyhemoglobin (35) . This results in the stoichiometric formation of methemoglobin and NO-from oxyhemoglobin and NO-(reaction [5] ).
tion. The creatinine clearance of MM patients was normal (mean = 122 ml/min). The creatinine clearance of RCC patients with unilateral nephrectomies was -50% ofnormal (mean = 59 ml/min). Exclusion criteria included pregnancy, active infection (including HIV), steroid therapy, organ allografts, brain metastases, or prior malignancy. All patients were treated for anticipated IL-2 toxicity with acetaminophen 650 mg p.o. every 4 h, indomethacin 25 mg p.o. every 6 h, and ranitidine 150 mg i.v. every 12 h. Patients also received meperidine 25-50 mg every 4 h i.v. as needed for chills due to IL-2 or LAK cell administration, as well as symptomatic treatment for pruritus, vomiting, or diarrhea as required. Each patient received highly purified recombinant human IL-2 from Escherichia coli (sp act 18 X 106 IU/mg) generously provided by Cetus Corp., Emeryville, CA, at 600,000 IU/kg i.v. every 8 h on days 1-5 (induction course). The IL-2 used in these experiments contained < 0.012 ng/ml LPS by Limulus amebocyte lysate assay (18 X (38, 39) . The following food groups were excluded: cured meats, malt, vegetables raw or cooked, including potatoes, melons, fish, imported cheese, and any fermented foods. The diet included milk, ice cream and domestic cheese, eggs, breads and cereals (including whole kernel corn), fresh meats (chicken, turkey, beef and pork), legumes, other fruits, hard candy and carbonated beverages, sugar, coffee, salt, and pepper. Daily enteral intake was also recorded and included in the calorie counts.
Measurement ofurine and blood NO-. Sequential 24-h urine specimens were collected throughout the study period. Bacterial growth in the urine during the collection period was prevented by placing 200 ml of 2-propanol into a 3-liter collection bottle. The samples were frozen at -80°C until a 1: 10 dilution of urine was assayed for NO; as previously described (24, 40 (Galbraith Laboratories, Knoxville, TN). HPLC and nuclear magnetic resonance analysis showed 1.5% L-ornithine and < 2% of the optical isomer D-[guanidino '5N2]arginine which is not a substrate for the cytokine-induced L-arginine/NO pathway (11, 12) . The remaining and major other component was unlabeled ammonium chloride. A 70 mM stock solution ofL-["5N]arginine prepared in sterile pyrogen-free water contained < 1 ng/ml of lipopolysaccharide (LPS) as measured by the Limulus amebocyte lysate assay. This stock solution was filtered three times (0. sured by gas chromatography-mass spectrometry (GC/MS) (model 5971, Hewlett-Packard Co., Palo Alto, CA), using electron ionization as previously described (41, 42) . GC/MS analysis was performed by Dr. David A. Wagner, Metabolic Solutions Inc., Acton, MA.
Determination of renal function. Glomerular filtration rate was monitored throughout by daily determination of endogenous creati-nine clearance. Renal handling of NOR, urea, sodium, and water was assessed as previously reported (43, 44) .
Statistical analysis. Statistical analysis was conducted using stepwise regression to evaluate differences among patients, followed by isolation of treatment effects as post-patient factors. Stepwise analysis ofcovariance procedure was used to compare periods of IL-2 administration vs. periods when patients were not receiving the drug. Two levels of prior comparisons were used. The first level tested for the presence of a linear (monotonically increasing or decreasing) trend within the four treatment phases of the study (two IL-2 and two offdrug) (45, 46) . In the second level, paired comparisons for differences among treatments were conducted, each averaging across the 5 d of observations within a treatment phase. The first compared the first IL-2 treatment with the first off-drug phase. The second compared the second IL-2 treatment with the second off-drug phase. The third contrast compared the first two treatment phases with the second two treatment phases and constituted a test ofthe reversibility and reproducibility of IL-2 therapy. Additional analyses were conducted to compare all possible pairs of treatments. Means for the four treatment phases were subjected to analysis of variance for repeated measurements. In case of overall significance, Newman-Keul's pairwise comparison ofthe differences between treatments was performed. All data are expressed as mean±SE. A P value of < 0.05 was taken to indicate significant differences.
Results
Baseline serum NO; and 24-h urine NO; output. Serum NO3 levels in six normal control individuals (four males and two females; mean age 38 yr) was 32±4 sumol/liter. The control individuals consumed a low nitrite (NO-/NO-) oral diet for 24 h and then fasted overnight (12 h) before donating blood for the NO-assay. In the current study, pretreatment serums were assayed for NO-. Baseline serum NO-for MM patients was 32±3.3 Amol/liter (n = 9) and for RCC patients 36±3.2 ,gmol/ liter (n = 5). The mean 24-h urinary NO-output for the patients on TPN before initiation of IL-2 therapy was 600±80 gmol (n = 5) for MM patients and 521±71 ,umol (n = 3) for RCC patients. This was similar to urinary NO-excretion (690 ,gmol/24 h) in eight healthy subjects with unrestricted activity (mean age 21 yr) on a low protein and low NO-/NO-oral diet (daily NO-ingestion < 180 ,umol) (47).
Effect ofIL-2 therapy on serum NO; levels. The 54 induction course of IL-2 therapy caused a significant rise of serum NO-levels in both RCC patients (Fig. 2 , left, panel a) and MM patients (Fig. 2, right, panel a) (Table I) .
Effect ofIL-2-induced changes in renalfunction on serum NO; levels and 24-h urine NO; excretion. The data were further analyzed in order to determine whether the IL-2-induced increase in serum NO-resulted from a primary rise in NOproduction or from decreased renal NO-excretion (see Fig. 2 sults confirmed that the IL-2-induced increase in urine and serum NO-was derived from a terminal guanidino nitrogen atom of L-arginine (data not shown). In summary, the '5N-labeling studies demonstrate that (a) IL-2 induces a marked increase in synthesis of NO-but not urea from a terminal guanidino nitrogen atom of L-arginine, and (b) the ratio of '5N-labeled molecules to unlabeled molecules remains constant regardless ofwhether synthesis was enhanced by IL-2 (NO-) or whether synthesis remained relatively unaltered (urea).
Effects ofIL-2 on peripheral vascular resistance and renal tubular function. Despite progressive declines in creatinine clearance (days 3-6; panel a), Fig. 4 (left) urine output of RCC patients receiving IL-2 was maintained with intravenous fluids, albumin infusions, furosemide, and dopamine as needed. Mean blood pressure (panel e) fell from 85±4 before IL-2 therapy to a nadir of 67±3 mmHg (P < 0.004) by day 4. This IL-2-induced decrease in creatinine clearance and blood pressure was associated with a marked increase in weight (from 69±5.2 to 73.7±5.7 kg on day 6 and profound reversible sodium retention (see Fig. 4 , left, panel b, P < 0.001). 2 d after discontinuation of IL-2, urine volume rose strikingly (from 1.9±0.5 on day 6 to 4.2±0.6 liter/24 h on day 7; P < 0.001). This diuresis persisted until day 11, when the second course of IL-2 was begun. Predictably, body weight fell and creatinine clearance and blood pressure rose simultaneously (both P < 0.01). The second course ofIL-2 produced a similar decrease in urine output and milder fall in blood pressure and again caused salt and water retention and thus weight gain. All alterations were readily reversible when IL-2 was discontinued. Both panels c ofFig. 4 illustrate the FE ofurea, another variable that can be used to assess changes in tubular reabsorption. Within 3 d of beginning IL-2 therapy, FE of urea decreased modestly, rose as IL-2 was discontinued, and fell again when IL-2 was readministered. This pattern demonstrates that IL-2 caused both enhanced Na and urea reabsorption. Panel dofFig. 4 (left) depicts the urine to plasma ratio of creatinine. As creatinine clearance and sodium excretion declined with IL-2 therapy (days 3-5), the urine to plasma ratio of creatinine fell from 40.7±4.4 to 23.3±9.8 (P < 0.003). A further decrease to a low of 11.2±3.2 occurred by day 7, a time when IL-2 had been discontinued and when creatinine clearance, blood pressure, urine volume, and salt excretion increased dramatically. Readministration of IL-2 on day 11 raised the urine to plasma ratio of creatinine to 70.1±3.0 (P < 0.001)). Taken together, these data demonstrate that proximal renal tubular function and the urinary concentrating capacity of patients with unilateral nephrectomies were preserved and not grossly affected by IL-2. Fig. 4 (right) summarizes the corresponding data from the MM patients. In general, the hemodynamic and renal responses to IL-2 administration were similar to those observed in RCC patients. It is of note, however, that virtually all functional changes were less severe when compared to those in RCC patients, whose baseline renal function was reduced because of prior unilateral nephrectomy. Finally, there was no evidence of major nephrogenous NO-production in either MM or RCC patients. The FE of NO-(panelsfin Fig. 2 ) was never greater than -40% indicating that , 60% ofthe filtered NO-was reabsorbed. Significant renal vascular or tubular NOproduction during IL-2 therapy would have caused the FE of NO-to rise further.
Discussion
In 1981 Green and co-workers (48) , while studying the biology ofnitrosamine carcinogenesis, reported metabolic balance studies that showed that conventional and germ-free rats synthesize NO-. This confirmed an earlier study suggesting that mammals, in addition to certain procaryotes, synthesized inorganic nitrogen oxides (49) . These workers also investigated NO-metabolism in long-term metabolic balance studies on healthy humans (47) . During one ofthese studies a human subject on a low NO-diet developed an unexpected increase ofNO-biosynthesis that occurred simultaneously with the onset offever and diarrhea (50 (11) . L-Arginine was converted to NO-and L-citrulline without loss of the guanidino carbon atom (12) . These experiments identified L-arginine as the precursor molecule for mammalian inorganic nitrogen oxide synthesis, L-citrulline as an additional product, and established a role for the L-arginine/ NO pathway as an effector mechanism ofcell-mediated immunity. NO was then demonstrated to be the precursor ofthe NO2
and NO-previously shown to be synthesized from L-arginine by activated macrophages (13, 15, 16 [64] ). Further support for this concept is derived from recent reports that NO may mediate TNFinduced vascular changes. N0-monomethyl-L-arginine reversed TNF (65) and endotoxin (66) induced decreased peripheral vascular resistance and mean arterial pressure in dogs. These studies provide evidence for a role for NO in the pathogenesis of decreased vascular resistance and hypotension observed in LPS-or TNF-treated dogs. It also has been demonstrated recently that IL-1 induces L-arginine-dependent cyclic GMP and NO production in rat vascular smooth muscle cells (67) . Therefore, it is reasonable to suggest that NO synthesis from L-arginine could play a major role in development of decreased vascular resistance and hypotension in IL-2-treated patients.
The current study provided an opportunity to evaluate renal function in humans under pathophysiological conditions that closely simulate endotoxin/LPS induced shock (hypotension and renal hypoperfusion) in a clinical setting associated with elevated levels of TNF in tissues. The data are consistent with the suggestion made by Marsden and Ballermann (68) that TNF-induced NO produced within the renal parenchyma actually protects against development ofacute tubular necrosis by maintaining postglomerular circulation. This is also consistent with the observation that synthesis of NO from L-arginine lessens hepatic damage in a murine model of endotoxin-induced shock (69) . NO reduces renal vascular resistance and inhibits platelet activation (aggregation and adhesion [70, 71] ). Thus NO has the potential to promote maintenance of renal perfusion under normal and pathological conditions (30, 53, 54, (70) (71) (72) (73) (74) . It is likely that cyclic GMP, a second messenger induced by NO, is elaborated by the kidney during IL-2 therapy (68, 73, 74) . It has been shown that atrial natriuretic factor, a peptide with vasodilating and diuretic/natriuretic properties, ameliorates, via cyclic GMP, the severity of acute renal failure (75, 76) .
The reversible form of IL-2-induced acute renal failure differs significantly from that observed in endotoxemic patients and animals (77) (78) (79) (80) (81) (82) . In the latter, acute and sometimes irreversible tubular necrosis is common. Specifically patients with endotoxin-induced acute tubular necrosis lose their capacity to retain salt (high FE of sodium) and to concentrate their urine (low urine to plasma creatinine ratio). These alterations were not observed in the IL-2-treated patients evaluated in this study (see Fig. 4 ). Since IL-2-treated patients resemble patients with endotoxemia in many regards (elevated TNF levels, hypotension, elevated cytokine levels, etc.), it is ofinterest that acute tubular necrosis is a rare consequence of IL-2 therapy. This observation is even more surprising since all patients received indomethacin, an agent that predisposes to the development of acute tubular necrosis (83) . In conclusion, the results reported here show highly significant NO-synthesis in patients receiving IL-2 therapy for advanced malignancy, and demonstrate that a cytokine-inducible high output L-arginine/NO pathway exists in humans.
